On air · 1 of 3 networks
Artivion, Inc.
- artivion.com
- Healthcare & Life Sciences
- US
- 995 employees
Artivion, Inc.’s ads on LinkedIn, Meta and Google, recorded by adsrunning. Browse the latest here for free. Sign up free to see all 145. Watch Artivion, Inc. with Starter to get each new one in your feed.
Watchlist with Starter · $49/mo
| Network | Status | Live ads | Nov 2025LinkedIn activity · 52 weeksOct 2026 | Checked | Next step |
|---|---|---|---|---|---|
| Running | 138 | Checked 30 Oct 2026 | See all 145 ads → | ||
| Meta | None recorded | 0 | No active ads recorded on the Meta Ad Library | Checked 17 Oct 2026 | Collect them with the API → |
| Recently | 16 | Ads on the Google Ads Transparency Center | Checked 5 Oct 2026 | Collect them with the API → |
Artivion, Inc. has 138 live LinkedIn ads. Its Facebook page had no active ads on 17 Oct 2026, and we recorded 16 Google ads on 5 Oct 2026.
Latest ads
- LINKEDIN · VIDEOSince 9 Sept 2026
Dr. Hiroo Takayama, Cardiothoracic Surgeon at Columbia University Medical Center, shares his perspective on how the Arcevo™ LSA device will affect arch repair of the left subclavian artery, allowing more patients to get the frozen elephant trunk and total arch repair in one procedure. 👉 Discover more about the ARTIZEN Pivotal Trial of the Arcevo LSA device here: https://lnkd.in/eEr59kZF
- LINKEDIN · VIDEOSince 9 Sept 2026
Watch Dr. T. Brett Reece, Cardiothoracic Surgeon at University of Colorado Anschutz Medical Campus, share his perspective on how the Arcevo™ LSA device is a welcome addition to the toolkit to approaching difficult aortic arch repairs involving the left subclavian artery. 👉 Discover more about the ARTIZEN Pivotal Trial of the Arcevo LSA device here: https://lnkd.in/eEr59kZF
- LINKEDIN · VIDEOSince 9 Sept 2026
Dr. Shinichi Fukuhara, Cardiothoracic Surgeon at University of Michigan Hospital, discusses the challenges of treating the left subclavian artery in aortic arch repair. Hear what he has to say about how the Arcevo™ LSA device will factor into his approach to the procedure. 👉 Discover more about the ARTIZEN Pivotal Trial of the Arcevo LSA device here: https://lnkd.in/eEr59kZF
- LINKEDIN · VIDEOSince 9 Sept 2026
Dr. Marijan Koprivanac, Cardiothoracic Surgeon at the Cleveland Clinic, shares his perspective on how the Arcevo™ LSA device will shape the approach to the frozen elephant trunk procedure for aortic arch repair. 👉 Discover more about the ARTIZEN Pivotal Trial of the Arcevo LSA device here: https://lnkd.in/eEr59kZF
- LINKEDIN · VIDEOSince 9 Sept 2026
Dr. Anthony Estrera, Cardiothoracic Surgeon at UT Health, shares his observations on how the Arcevo ™ LSA device affects his approach to arch repair of the left subclavian artery. 👉 Discover more about the ARTIZEN Pivotal Trial of the Arcevo LSA device here: https://lnkd.in/eEr59kZF
- LINKEDIN · VIDEOSince 29 Jun 2026
Artivion is proud to announce that the FDA has approved the premarket approval application (PMA) for the AMDS™ Hybrid Prosthesis. "This approval, following our recent acquisition of the PMA-approved NEXUS system and continued clinical trial enrollment progress for ARCEVO LSA, marks another step forward in our vision of Artivion as the only company globally with a complete portfolio of market leading aortic arch solutions”, said Pat Mackin, Chairman, President and CEO. This achievement is an important milestone in advancing treatment options for aortic disease. For more details, access the press release here: https://lnkd.in/e6WZuWfK
6 of 145 adsSign up to see every Artivion, Inc. ad, filter by format and date, and get alerts on new ones.
See all 145 adsWatch the companies you care about.
Filter every ad by industry, country, format and network, and get alerts when a company you watch starts running new ads.